Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks — Connecticut, December 2020–February 2021
| Autor: | John A. Jernigan, Stephen M. Bart, Stephanie J. Schrag, Chris Edens, Kara Jacobs Slifka, Kerui Xu, Elizabeth Soda, Sunil Parikh, Adora Harizaj, Jillian N. Armstrong, Gordana Derado, Hanna Y. Ehrlich, Amadea Britton, Jennifer R. Verani, Vivian Leung, Srinivas Nanduri, Nong Shang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty Health (social science) COVID-19 Vaccines Epidemiology Health Toxicology and Mutagenesis Population MEDLINE Pharmacy 01 natural sciences Disease Outbreaks 03 medical and health sciences 0302 clinical medicine Health Information Management medicine Humans 030212 general & internal medicine Full Report 0101 mathematics education Immunization Schedule Aged Retrospective Studies Skilled Nursing Facilities Aged 80 and over education.field_of_study business.industry Public health 010102 general mathematics Outbreak COVID-19 Retrospective cohort study General Medicine Middle Aged Clinical trial Vaccination Connecticut Family medicine Female business |
| Zdroj: | Morbidity and Mortality Weekly Report |
| ISSN: | 1545-861X 0149-2195 |
| Popis: | Residents of long-term care facilities (LTCFs), particularly those in skilled nursing facilities (SNFs), have experienced disproportionately high levels of COVID-19-associated morbidity and mortality and were prioritized for early COVID-19 vaccination (1,2). However, this group was not included in COVID-19 vaccine clinical trials, and limited postauthorization vaccine effectiveness (VE) data are available for this critical population (3). It is not known how well COVID-19 vaccines protect SNF residents, who typically are more medically frail, are older, and have more underlying medical conditions than the general population (1). In addition, immunogenicity of the Pfizer-BioNTech vaccine was found to be lower in adults aged 65-85 years than in younger adults (4). Through the CDC Pharmacy Partnership for Long-Term Care Program, SNF residents and staff members in Connecticut began receiving the Pfizer-BioNTech COVID-19 vaccine on December 18, 2020 (5). Administration of the vaccine was conducted during several on-site pharmacy clinics. In late January 2021, the Connecticut Department of Public Health (CT DPH) identified two SNFs experiencing COVID-19 outbreaks among residents and staff members that occurred after each facility's first vaccination clinic. CT DPH, in partnership with CDC, performed electronic chart review in these facilities to obtain information on resident vaccination status and infection with SARS-CoV-2, the virus that causes COVID-19. Partial vaccination, defined as the period from >14 days after the first dose through 7 days after the second dose, had an estimated effectiveness of 63% (95% confidence interval [CI] = 33%-79%) against SARS-CoV-2 infection (regardless of symptoms) among residents within these SNFs. This is similar to estimated effectiveness for a single dose of the Pfizer-BioNTech COVID-19 vaccine in adults across a range of age groups in noncongregate settings (6) and suggests that to optimize vaccine impact among this population, high coverage with the complete 2-dose series should be recommended for SNF residents and staff members. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|